Multiplex PCR theranostics of severe respiratory infections

Pozzetto, Bruno; Grattard, Florence; Pillet, Sylvie

doi:10.1586/eri.09.131

Cited by 16 publications

(12 citation statements)

References 27 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DFA that uses monoclonal antibodies and is performed directly on specimens and on SVC after 24-48 h incubation has been incorporated for detection of parainfluenza virus 1, 2, and 3 96 . Monoclonal antibodies for parainfluenza 4 have not yet been approved for diagnostic purposes. The sensitivity of DFA compared to cell culture varies between laboratories and patient populations, and has ranged from 70% to 83% 98 .…”

Section: Parainfluenza Virusmentioning

confidence: 99%

“…Respiratory tract infection can lead to acute asthma exacerbations, acute otitis media, or other lower respiratory tract presentations, including bronchitis, brochiolitis, and pneumonia. In 2002, LRTI (lower respiratory tract infection) accounted for approximately 4 million deaths world-wide, and 7% of all deaths 4 . In clinical practice a specific virus is often not identified, due to the lack of available sensitive tests, the presence of as-yet unidentified pathogens, or the failure to use appropriate tests.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular diagnosis of respiratory virus infections

Mahony¹,

Petrich²,

Śmieja³

2011

Critical Reviews in Clinical Laboratory Sciences

192

181

View full text Add to dashboard Cite

The appearance of eight new respiratory viruses, including the SARS coronavirus in 2003 and swine-origin influenza A/H1N1 in 2009, in the human population in the past nine years has tested the ability of virology laboratories to develop diagnostic tests to identify these viruses. Nucleic acid based amplification tests (NATs) for respiratory viruses were first introduced two decades ago and today are utilized for the detection of both conventional and emerging viruses. These tests are more sensitive than other diagnostic approaches, including virus isolation in cell culture, shell vial culture (SVC), antigen detection by direct fluorescent antibody (DFA) staining, and rapid enzyme immunoassay (EIA), and now form the backbone of clinical virology laboratory testing around the world. NATs not only provide fast, accurate and sensitive detection of respiratory viruses in clinical specimens but also have increased our understanding of the epidemiology of both new emerging viruses such as the pandemic H1N1 influenza virus of 2009, and conventional viruses such as the common cold viruses, including rhinovirus and coronavirus. Multiplex polymerase chain reaction (PCR) assays introduced in the last five years detect up to 19 different viruses in a single test. Several multiplex PCR tests are now commercially available and tests are working their way into clinical laboratories. The final chapter in the evolution of respiratory virus diagnostics has been the addition of allelic discrimination and detection of single nucleotide polymorphisms associated with antiviral resistance. These assays are now being multiplexed with primary detection and subtyping assays, especially in the case of influenza virus. These resistance assays, together with viral load assays, will enable clinical laboratories to provide physicians with new and important information for optimal treatment of respiratory virus infections.

show abstract

Section: Parainfluenza Virusmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Molecular diagnosis of respiratory virus infections

Mahony¹,

Petrich²,

Śmieja³

2011

Critical Reviews in Clinical Laboratory Sciences

192

181

View full text Add to dashboard Cite

show abstract

“…One of the main challenges in the therapeutic management of infectious diseases remains the soaring phenomenon of antibiotic and antiviral resistance. The advent of effective genotyping techniques has created many expectations for the development of multiple rapid diagnostic opportunities that will slowly replace classical phenotypic methods for identifying microbes and determining their antimicrobial susceptibility pattern 38 . At the same time, the growing burden of chronic viral diseases (such as AIDS, hepatitis C and B) has increased the pressure on the identification of strategies targeting the reduction in adverse drug reactions (ADRs) frequently encountered in a significant proportion of patients treated with antiviral drugs.…”

Section: Discussionmentioning

confidence: 99%

Economic evaluations of pharmacogenetic approaches in infectious diseases: a review of current approaches and evaluation of critical aspects affecting their quality

Meoni¹

2013

J Public Health Africa

View full text Add to dashboard Cite

Pharmacogenetics holds great potential for improving the effectiveness of treatment modalities in infectious diseases by taking into account the genetic determinants of both the host and infectious agents’ individuality. Better utilization of resources and improved therapeutic efficiency are the expected outcomes of personalized medicine using pharmacogenetic and pharmacogenomics information made available by technological advances. However, there has been growing concern in the clinical community regarding the evaluation of the true benefits of these approaches. This perception is partly due to the limited number and perceived poor quality of economic evaluations in this field, and initiatives aimed at harmonizing and communicating strategies improving the quality of these studies and their acceptance by the clinical community are greatly needed. This paper reviews current literature of economic evaluations of pharmacogenetics interventions guiding pharmacotherapy in infectious diseases. PubMed and the NHS Centre for Reviews and Dissemination databases were searched using a combination of five broad research terms related to pharmacogenetic approaches, and papers relative to economic evaluations of pharmacogenetic interventions in infectious diseases retained for further analysis. Using these criteria, a total of 14 papers were included in this review. The area of economic evaluation of pharmacogenetic interventions in infectious diseases remains understudied and would benefit from greater harmonization. The main weaknesses of evaluations reviewed in this paper seem to be represented by poor evidence of pharmacogenetic marker validation, inconsistencies in the selection of costs and utility included in the economic models and the choice of sensitivity analysis. All these factors limit the overall transparency of the studies, greater acceptance of their results and applicability to diverse and possibly resourcelimited environments where these approaches could be expected to have the greater impact.

show abstract

“…Conventional culture-based methods are slow to give definitive results. Rapid culture-independent methods contribute to a better initial management of patients and more efficient use of antimicrobials (Picard & Bergeron, 2002;Bissonnette & Bergeron, 2006;Pozzetto et al, 2010). Culture-independent methods such as nucleic acid amplification tests are being increasingly used for diagnosis of infectious diseases.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of the FilmArray blood culture identification panel for direct molecular diagnosis of infectious diseases from samples other than blood

Micó

Navarro

Miniac

et al. 2015

Journal of Medical Microbiology

View full text Add to dashboard Cite

Molecular-based techniques reduce the delay in diagnosing infectious diseases and therefore contribute to better patient outcomes. We assessed the FilmArray blood culture identification (BCID) panel (Biofire Diagnostics/bioMé rieux) directly on clinical specimens other than blood: cerebrospinal, joint, pleural and ascitic fluids, bronchoscopy samples and abscesses. We compared the results from 88 samples obtained by culture-based techniques. The percentage of agreement between the two methods was 75 % with a Cohen k value of 0.51. Global sensitivity and specificity using the FilmArray BCID panel were 71 and 97 %, respectively. Sensitivity was poorer in samples with a low bacterial load, such as ascitic and pleural fluids (25 %), whereas the sensitivity for abscess samples was high (89 %). These findings suggest that the FilmArray BCID panel could be useful to perform microbiological diagnosis directly from samples other than positive blood cultures, as it offers acceptable sensitivity and moderate agreement with conventional microbiological methods. Nevertheless, cost-benefit studies should be performed before introducing this method into algorithms for microbiological diagnostics.

show abstract

Multiplex PCR theranostics of severe respiratory infections

Cited by 16 publications

References 27 publications

Molecular diagnosis of respiratory virus infections

Molecular diagnosis of respiratory virus infections

Economic evaluations of pharmacogenetic approaches in infectious diseases: a review of current approaches and evaluation of critical aspects affecting their quality

Efficacy of the FilmArray blood culture identification panel for direct molecular diagnosis of infectious diseases from samples other than blood

Contact Info

Product

Resources

About